AzurRx BioPharma (NASDAQ:AZRX) resumed with Buy rating and $7 (554% upside) price target at Roth Capital Partners.
IVERIC bio (NASDAQ:ISEE) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company.
Matinas BioPharma Holdings (NYSEMKT:MTNB) initiated with Buy rating and $3 (99% upside) price target at SunTrust. Shares up 5% premarket.
Pacira BioSciences (NASDAQ:PCRX) initiated with Buy rating and $60 (37% upside) price target at SunTrust.
Provention Bio (NASDAQ:PRVB) initiated with Overweight rating and $25 (51% upside) price target at Cantor Fitzgerald. Shares up 3% premarket.
BioMarin Pharmaceutical (NASDAQ:BMRN) upgraded to Outperform with a $113 (32% upside) price target at RBC citing bullish prospects for hemophilia gene therapy valrox.
DaVita (NYSE:DVA) upgraded to Buy with a $97 (20% upside) price target at Goldman Sachs. Shares up 2% premarket.
BioNTech SE (NASDAQ:BNTX) downgraded to Market Perform with a $31 (16% downside risk) price target at SVB Leerink. Shares down 2% premarket.
Epizyme (NASDAQ:EPZM) downgraded to Market Perform with an $18 (33% downside risk) price target at SVB Leerink. Shares down 5% premarket.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) downgraded to Hold at Gabelli.
https://seekingalpha.com/news/3534298-rbc-likes-biomarin-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.